Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.

Datacor acquired MySep to expand its engineering software portfolio. Agilent Technologies agreed to buy Proscia for up to $270M to enhance digital pathology. Payward, parent of Kraken, will acquire Saldo Bank to expand European banking infrastructure. Terms for the latter two deals were not disclosed.

Agilent (A) will acquire Proscia for up to $270m, including $240m upfront and $30m for performance milestones. The deal aims to enhance Agilent's pathology portfolio with Proscia's digital pathology software, Concentriq Dx, which has FDA clearance. Proscia serves over 4,000 labs and 16 top pharma companies, according to Agilent. The acquisition is expected to close in Agilent's fiscal year 2027.

JPMorgan raised its price target for Agilent Technologies to $195 from $190. UBS also increased its target to $180 from $165. Agilent's stock is up 1.34% year-to-date and 26.11% over 5 days.